Billanna Hwang1, W Conrad Liles2, Rachel Waworuntu3, Michael S Mulligan4. 1. Department of Surgery, University of Washington School of Medicine, Seattle, Wash; Center for Lung Biology, University of Washington, Seattle, Wash. Electronic address: bhwang@uw.edu. 2. Center for Lung Biology, University of Washington, Seattle, Wash; Department of Medicine, University of Washington School of Medicine, Seattle, Wash. 3. Center for Lung Biology, University of Washington, Seattle, Wash. 4. Department of Surgery, University of Washington School of Medicine, Seattle, Wash; Center for Lung Biology, University of Washington, Seattle, Wash.
Abstract
OBJECTIVE: Mesenchymal stromal cell-based therapies have demonstrated efficacy in treating a variety of diseases. Despite the potential benefits, there are still significant hurdles that need to be overcome for clinical use. We describe a cell-free-based immunotherapy approach for inducing pulmonary ischemic tolerance by using mesenchymal stromal cell-conditioned media. METHODS: In our well-established lung ischemia-reperfusion model, we pretreated with mesenchymal stromal cell-conditioned media 30 minutes before injury. To determine the degree of lung injury, we assessed for changes in lung vascular permeability, proinflammatory cytokines and cellular infiltrates in bronchoalveolar lavage, and histopathology. Macrophage and T-cell subsets were assessed by immunohistochemistry. RESULTS: Pretreatment with mesenchymal stromal cell-conditioned media conferred protection against lung ischemia-reperfusion injury. This protection is characterized by a significant reduction in proinflammatory cytokines, a decrease in infiltrating inflammatory cells, and increases in M2-like macrophages and regulatory T cells. CONCLUSIONS: Cell-free mesenchymal stromal cell-conditioned media therapy confers pulmonary ischemic tolerance. This therapy uses paracrine factors that provide beneficial protective effects by immunomodulating the inflammatory response in resident and infiltrating cell subsets.
OBJECTIVE: Mesenchymal stromal cell-based therapies have demonstrated efficacy in treating a variety of diseases. Despite the potential benefits, there are still significant hurdles that need to be overcome for clinical use. We describe a cell-free-based immunotherapy approach for inducing pulmonary ischemic tolerance by using mesenchymal stromal cell-conditioned media. METHODS: In our well-established lung ischemia-reperfusion model, we pretreated with mesenchymal stromal cell-conditioned media 30 minutes before injury. To determine the degree of lung injury, we assessed for changes in lung vascular permeability, proinflammatory cytokines and cellular infiltrates in bronchoalveolar lavage, and histopathology. Macrophage and T-cell subsets were assessed by immunohistochemistry. RESULTS: Pretreatment with mesenchymal stromal cell-conditioned media conferred protection against lung ischemia-reperfusion injury. This protection is characterized by a significant reduction in proinflammatory cytokines, a decrease in infiltrating inflammatory cells, and increases in M2-like macrophages and regulatory T cells. CONCLUSIONS: Cell-free mesenchymal stromal cell-conditioned media therapy confers pulmonary ischemic tolerance. This therapy uses paracrine factors that provide beneficial protective effects by immunomodulating the inflammatory response in resident and infiltrating cell subsets.
Authors: M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz Journal: Cytotherapy Date: 2006 Impact factor: 5.414
Authors: Jason D Christie; Jeffrey S Sager; Stephen E Kimmel; Vivek N Ahya; Christina Gaughan; Nancy P Blumenthal; Robert M Kotloff Journal: Chest Date: 2005-01 Impact factor: 9.410
Authors: Randy P Carney; Sidhartha Hazari; Macalistair Colquhoun; Di Tran; Billanna Hwang; Michael S Mulligan; James D Bryers; Eugenia Girda; Gary S Leiserowitz; Zachary J Smith; Kit S Lam Journal: Anal Chem Date: 2017-04-25 Impact factor: 6.986
Authors: Andrew E Gelman; Andrew J Fisher; Howard J Huang; Maher A Baz; Ciara M Shaver; Thomas M Egan; Micheal S Mulligan Journal: J Heart Lung Transplant Date: 2017-07-24 Impact factor: 10.247